Collaboration to Discover Therapeutic Oncology Leads

Under a strategic partnership IONTAS Ltd, a leader in the discovery and optimisation of fully human antibodies and aTen Therapeutics Ltd, developers of next-generation antibodies for the treatment of cancer, will combine their resources to deliver antibodies against biological targets.

Dr John McCafferty, CEO and Founder of IONTAS, said: “The use of traditional in vivo technologies can work well to generate simple therapeutic antibodies, but with increasing requirements for specificity, function, developability and affinity, these traditional approaches are not always appropriate. IONTAS will apply its technologies to overcome limitations of other platforms to generate therapeutic leads against pre-defined specification from aTen, to help its current pipeline progress.”

Prof Chris Wood, Chairman and Founder of aTen, commented: “IONTAS was selected because of its technological expertise and proven track record of delivering antibodies to all its partners. We value the extensive experience IONTAS can add to advancing aTen’s therapeutic programs in the fight against cancer.”